Cardiotoxic chemotherapy drugs

cardiotoxicity - Left ventricular dysfunction associated with chemotherapy drugs Cardiotoxicity of cancer chemotherapy agents other

While antimicrotubular agents such as the taxanes cause cardiotoxicities that include heart block, hypertension, arrythmias, and CHF, recent study of taxane cardiotoxicity has explored if they exacerbate toxicity of other chemotherapy drugs such as anthracyclines or trastuzumab [2,30].

Definition of Chemotherapy Induced Cardiotoxicity Defined traditionally as a decrease in LVEF due to chemotherapy PREDICT Trial Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment Cardiotoxicity defined as presentation of one or more cardiac events within 12 months of initiation of chemotherapy

Unfortunately, anthracyclines are considered the principal culprit drugs behind chemotherapy-induced cardiotoxicity (1 5). The pathognomonic manifestation of anthracycline-induced cardiotoxicity is a hypokinetic cardiomyopathy progressively leading to heart failure, first described in 2024 ( 6 ).

The cardiotoxicity of chemotherapy agents other than fluoropyrimidines, anthracyclines, and HER2-targeted therapies will be reviewed here.

The physiology of the heart and the effect of drugs in children vary vividly from adults; therefore, it is crucial to study the cardiotoxic effect of chemotherapy drugs in the pediatric population. This review highlights the potential contributing factors for cardiotoxicity in the pediatric population and discusses the identification and

by S Laksono 2024In addition, several studies have shown that it is often treated using chemotherapy drugs cardiotoxicity in breast cancer patients receiving chemotherapy

by S Laksono 2024Cisplatin chemotherapy, on the other hand, is linked to cardiotoxicity Arrhythmias such as SVT have been associated with chemotherapy drugs. Hence

Less cardiotoxic chemotherapeutic agents and anti-remodelling drugs such as a beta-blockers, ACE inhibitors or angiotensin receptor blockers before chemotherapy may theoretically prevent cardiotoxicity in high risk patients.